StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Pelthos Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Pelthos Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -133.4%. For fiscal 2025 it was -193.1%.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-193.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-111.0%–
Q1 FY2026Mar 31, 2026-120.0%–
Q4 FY2025Dec 31, 2025-127.8%–
Q3 FY2025Sep 30, 2025-207.4%–

More Pelthos Therapeutics figures

See a number that looks wrong?